Sequential Administration of Anti-Complement Component C5 Eculizumab and Type-2 Anti-Cd20 Obinutuzumab for the Treatment of Early Antibody-Mediated Rejection after Kidney Transplantation: A Proof of Concept
CLINICAL IMMUNOLOGY（2024）
关键词
Obinutuzumab,Eculizumab,Antibody -mediated rejection,Kidney transplant,Immunosuppression,Treatment
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要